Publications by authors named "Samuel I Anyanwu"
Article Synopsis
- Upadacitinib, an oral Janus kinase inhibitor, showed effectiveness in treating moderate-to-severe Crohn's disease through phase 3 trials, specifically focusing on patients with fistulizing disease.
- * In these studies, patients with fistulas were treated with either upadacitinib or a placebo, and outcomes included resolution of drainage and closure of external openings.
- * Results indicated that upadacitinib significantly improved rates of drainage resolution and closure of perianal fistulas compared to placebo, showing promising clinical benefits for this patient group.
Background & Aims: Upadacitinib, an oral Janus kinase inhibitor, achieved significantly higher rates of clinical remission and endoscopic response vs placebo during induction (U-EXCEL [NCT03345849], U-EXCEED [NCT03345836]) and maintenance (U-ENDURE [NCT03345823]) treatment in patients with moderate-to-severe Crohn's disease. Prior biologic failure is often associated with reduced responses to subsequent therapies. This post hoc analysis assessed upadacitinib efficacy by prior biologic failure status.
View Article and Find Full Text PDFArticle Synopsis
- Upadacitinib (UPA) is an oral treatment approved for Crohn's disease (CD) that aims for quick symptomatic relief in patients.
- A study pooled data from three trials to investigate how quickly patients experienced improvement in stool frequency and abdominal pain when treated with UPA or a placebo.
- Results showed that patients on UPA saw significant improvements within 5-6 days, achieving remission faster than those on placebo, leading to higher rates of clinical remission and response by week 2.
Objective: Treatment guidelines for rheumatoid arthritis (RA) recommend targeting low disease activity or remission and switching therapies for patients not reaching those targets. We evaluated real-world use of disease activity measures, treatment discontinuation, and switching patterns among patients with RA initiating a first-line tumor necrosis factor inhibitor (TNFi).
Methods: Data from adult patients with RA initiating a first-line TNFi were collected from the American Rheumatology Network (January 2014-August 2021).
Article Synopsis
- This article investigates cancer occurrences in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA) who were treated with upadacitinib (UPA) compared to other treatments.
- The study analyzed data from 11 phase 3 clinical trials, assessing adverse events related to treatment, specifically focusing on malignancies and distinguishing between nonmelanoma skin cancer and other cancers.
- The findings indicate comparable rates of cancer (excluding nonmelanoma skin cancer) across different treatments, with a notable increase in nonmelanoma skin cancer rates
Background: Extracellular vesicles (EVs) are membrane bound, secreted by cells, and detected in bodily fluids, including urine, and contain proteins, RNA, and DNA. Our goal was to identify HIV and human proteins (HPs) in urinary EVs from HIV+ patients and compare them to HIV- samples.
Methods: Urine samples were collected from HIV+ ( = 35) and HIV- ( = 12) individuals.